Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Risk Stratification in People with Diabetes for Fasting During Ramadan: Consensus from Arabic Association for the Study of Diabetes and Metabolism

Author(s): Inass Shaltout*, Amr Mahmoud Abdelwahab, Amr El Meligi, Hany Hammad, Shereen Abdelghaffar, Atef Elbahry, Nasser Taha, Nehal Hamdy Elsaid, Amr Gad, Laila Hammouda, Shaymaa Abdelmaboud and Amin Roshdy Soliman

Volume 20, Issue 7, 2024

Published on: 20 October, 2023

Article ID: e201023222409 Pages: 22

DOI: 10.2174/0115733998249793231005105724

open access plus

Abstract

Background: Current international guidelines recommend a pre-Ramadan risk assessment for people with diabetes (PwDM) who plan on fasting during the Holy month. However, a comprehensive risk assessment-based recommendation for the management of PwDM intending to fast is still controversial. Therefore, the Arabic Association for the Study of Diabetes and Metabolism (AASD) developed this consensus to provide further insights into risk stratification in PwDM intending to fast during Ramadan.

Methods: The present consensus was based on the three-step modified Delphi method. The modified Delphi method is based on a series of voting rounds and in-between meetings of the expert panel to reach agreements on the statements that did not reach the consensus level during voting. The panel group comprised professors and consultants in endocrinology (both adult and pediatric). Other members included experts in the fields of cardiovascular medicine, nephrology, ophthalmology, and vascular surgery, affiliated with academic institutions in Egypt.

Result: In PwDM who intend to fast during Ramadan, risk stratification is crucial to optimize patient outcomes and prevent serious complications. The present consensus provides risk assessment of those living with diabetes according to several factors, including the type of diabetes, presence, and severity of complications, number of fasting hours, and other socioeconomic factors. According to their risk factors, patients were classified into four categories (very high, high, moderate, and low risk).

Conclusion: Future research is warranted due to the controversial literature regarding the impact of fasting on certain comorbidities.

Keywords: Diabetes, type 2 diabetes, type 1 diabetes, fasting, ramadan, risk stratification.

[1]
Ibrahim M, Davies MJ, Ahmad E, et al. Recommendations for management of diabetes during Ramadan: Update 2020, applying the principles of the ADA/EASD consensus. BMJ Open Diabetes Res Care 2020; 8(1): e001248.
[http://dx.doi.org/10.1136/bmjdrc-2020-001248] [PMID: 32366501]
[2]
Hassanein M, Al-Arouj M, Hamdy O, et al. Diabetes and Ramadan: Practical guidelines. Diabetes Res Clin Pract 2017; 126: 303-16.
[http://dx.doi.org/10.1016/j.diabres.2017.03.003] [PMID: 28347497]
[3]
Hassanein M, Afandi B, Yakoob Ahmedani M, et al. Diabetes and Ramadan: Practical guidelines 2021. Diabetes Res Clin Pract 2022; 185: 109185.
[http://dx.doi.org/10.1016/j.diabres.2021.109185] [PMID: 35016991]
[4]
Zilbermint M. Diabetes and climate change. J Community Hosp Intern Med Perspect 2020; 10(5): 409-12.
[http://dx.doi.org/10.1080/20009666.2020.1791027] [PMID: 33235673]
[5]
The New Arab Staff. Middle Eastern cities record highest world temperatures. The New Arab 2022; p. 19.
[6]
World climate guide. Climates to Travel. 2021.https://www.climatestotravel.com/
[7]
El Hefnawy MHMF, Abdelaaty TAF, Bassyouni AA, et al. Hypoglycemia among insulin-treated patients with diabetes: Egypt cohort of IO HAT Study. Open Diabetes J 2018; 8(1): 34-47.
[http://dx.doi.org/10.2174/1876524601808010034]
[8]
Hegazi R, El-Gamal M, Abdel-Hady N, Hamdy O. Epidemiology of and risk factors for type 2 diabetes in Egypt. Ann Glob Health 2016; 81: 814.
[http://dx.doi.org/10.1016/j.aogh.2015.12.011]
[9]
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111-88.
[http://dx.doi.org/10.1093/eurheartj/ehz455] [PMID: 31504418]
[10]
Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: How to decide its appropriateness. World J Methodol 2021; 11(4): 116-29.
[http://dx.doi.org/10.5662/wjm.v11.i4.116] [PMID: 34322364]
[11]
Wright JG, Swiontkowski MF, Heckman JD. Introducing levels of evidence to the journal. J Bone Joint Surg Am 2003; 85(1): 1-3.
[http://dx.doi.org/10.2106/00004623-200301000-00001] [PMID: 12533564]
[12]
Lynn MR. Determination and quantification of content validity. Nurs Res 1986; 35(6): 382-6.
[http://dx.doi.org/10.1097/00006199-198611000-00017] [PMID: 3640358]
[13]
Al Awadi FF, Echtay A, Al Arouj M, et al. Patterns of diabetes care among people with type 1 diabetes during ramadan: An international prospective study (DAR-MENA T1DM). Adv Ther 2020; 37(4): 1550-63.
[http://dx.doi.org/10.1007/s12325-020-01267-4] [PMID: 32144714]
[14]
Hassanein M, Al Awadi FF, El Hadidy KES, et al. The characteristics and pattern of care for the type 2 diabetes mellitus population in the MENA region during Ramadan: An international prospective study (DAR-MENA T2DM). Diabetes Res Clin Pract 2019; 151: 275-84.
[http://dx.doi.org/10.1016/j.diabres.2019.02.020] [PMID: 30825560]
[15]
Aravind SR, Tayeb KA, Ismail SB, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: A five-country observational study. Curr Med Res Opin 2011; 27(6): 1237-42.
[http://dx.doi.org/10.1185/03007995.2011.578245] [PMID: 21506631]
[16]
Al-Arouj M, Hassoun AAK, Medlej R, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: The VIRTUE study. Int J Clin Pract 2013; 67(10): 957-63.
[http://dx.doi.org/10.1111/ijcp.12243] [PMID: 24001317]
[17]
Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: The STEADFAST study. Vasc Health Risk Manag 2014; 10: 319-26.
[PMID: 24920915]
[18]
Glimepiride in Ramadan (GLIRA) Study Group The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care 2005; 28(2): 421-2.
[http://dx.doi.org/10.2337/diacare.28.2.421] [PMID: 15677804]
[19]
Hassanein M, Al Sifri S, Shaikh S, et al. A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN. Diabetes Res Clin Pract 2020; 163: 108154.
[http://dx.doi.org/10.1016/j.diabres.2020.108154] [PMID: 32330510]
[20]
Papanas N, Katsiki N, Hatzitolios AI, Maltezos E. Pioglitazone: A valuable component of combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother 2011; 12(10): 1457-61.
[http://dx.doi.org/10.1517/14656566.2011.568477]
[21]
Thomas N, Bharani , Ameen M, et al. A double-blind, randomized, multicenter study evaluating the effects of pioglitazone in fasting Muslim subjects during Ramadan. Int J Diabetes Dev Ctries 2006; 26(2): 70-6.
[http://dx.doi.org/10.4103/0973-3930.28276]
[22]
Bakiner O, Ertorer ME, Bozkirli E, Tutuncu NB, Demirag NG. Repaglinide plus single-dose insulin glargine: A safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Acta Diabetol 2009; 46(1): 63-5.
[http://dx.doi.org/10.1007/s00592-008-0062-7] [PMID: 18825302]
[23]
Cesur M, Corapcioglu D, Gursoy A, et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract 2007; 75(2): 141-7.
[http://dx.doi.org/10.1016/j.diabres.2006.05.012] [PMID: 16815586]
[24]
Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2002; 58(1): 45-53.
[http://dx.doi.org/10.1016/S0168-8227(02)00104-3] [PMID: 12161056]
[25]
Anwar A, Azmi KN, Hamidon BB, Khalid BA. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan. Med J Malaysia 2006; 61(1): 28-35.
[PMID: 16708731]
[26]
Al Sifri S, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: A randomised trial. Int J Clin Pract 2011; 65(11): 1132-40.
[http://dx.doi.org/10.1111/j.1742-1241.2011.02797.x] [PMID: 21951832]
[27]
Aravind SR, Ismail SB, Balamurugan R, et al. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: A randomized, pragmatic study. Curr Med Res Opin 2012; 28(8): 1289-96.
[http://dx.doi.org/10.1185/03007995.2012.707119] [PMID: 22738801]
[28]
Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: Results of the VECTOR study. Curr Med Res Opin 2011; 27(7): 1367-74.
[http://dx.doi.org/10.1185/03007995.2011.579951] [PMID: 21568833]
[29]
Shete A, Shaikh A, Nayeem KJ, et al. Vildagliptin vs. sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan. World J Diabetes 2013; 4(6): 358-64.
[http://dx.doi.org/10.4239/wjd.v4.i6.358] [PMID: 24379927]
[30]
Loh HH, Yee A, Loh HS, Sukor N, Kamaruddin NA. Comparative studies of dipeptidyl peptidase 4 inhibitor vs. sulphonylurea among Muslim type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis. Prim Care Diabetes 2016; 10(3): 210-9.
[http://dx.doi.org/10.1016/j.pcd.2015.09.001] [PMID: 26392074]
[31]
el Hefnawy H, Abdel HMM, el Sayed El Hadidy K, Ramadan H, Reda IA, Kamel A, et al. Safety and efficacy of SGLT2 inhibitors versus DPP4 inhibitors in fasting patients with T2-diabetes mellitus during ramadan in Egypt (EMPA-Ramadan). Int J Endocrinol 2022; 7(81)
[32]
Hassanein M, Bashier A, Randeree H, et al. Use of SGLT2 inhibitors during Ramadan: An expert panel statement. Diabetes Res Clin Pract 2020; 169: 108465.
[http://dx.doi.org/10.1016/j.diabres.2020.108465] [PMID: 32971151]
[33]
Wan Seman WJ, Kori N, Rajoo S, et al. Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia. Diabetes Obes Metab 2016; 18(6): 628-32.
[http://dx.doi.org/10.1111/dom.12649] [PMID: 26889911]
[34]
Hassanein M, Echtay A, Hassoun A, et al. Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS). Int J Clin Pract 2017; 71(10): e12991.
[http://dx.doi.org/10.1111/ijcp.12991] [PMID: 28851109]
[35]
Abdelgadir E, Rashid F, Bashier A, et al. Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes. Diabetes Metab Syndr 2019; 13(5): 2927-32.
[http://dx.doi.org/10.1016/j.dsx.2019.07.055] [PMID: 31425958]
[36]
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA. Liraglutide and cardiovascular outcomes in type 2 diabetes. Drug Ther Bull 2016; 54: 101.
[http://dx.doi.org/10.1056/NEJMoa1603827]
[37]
Hassanein M, Buyukbese MA, Malek R, et al. Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: The observational ORION study. Diabetes Res Clin Pract 2020; 166: 108189.
[http://dx.doi.org/10.1016/j.diabres.2020.108189] [PMID: 32360709]
[38]
Salti I. Efficacy and safety of insulin glargine and glimepiride in subjects with type 2 diabetes before, during and after the period of fasting in Ramadan. Diabet Med 2009; 26(12): 1255-61.
[http://dx.doi.org/10.1111/j.1464-5491.2009.02836.x] [PMID: 20002478]
[39]
Anyanwagu U, Mamza J, Gordon J, Donnelly R, Idris I. Premixed vs. basal-bolus insulin regimen in type 2 diabetes: Comparison of clinical outcomes from randomized controlled trials and real-world data. Diabet Med 2017; 34(12): 1728-36.
[http://dx.doi.org/10.1111/dme.13518] [PMID: 28945928]
[40]
Mattoo V, Milicevic Z, Malone JK, et al. A comparison of insulin lispro Mix25™ and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract 2003; 59(2): 137-43.
[http://dx.doi.org/10.1016/S0168-8227(02)00202-4] [PMID: 12560163]
[41]
Soewondo P, Adam J, Sanusi H, Soeatmadji D A. A Multicenter, prospective, non-interventional evaluation of efficacy and safety of using biphasic insulin aspart as monotherapy, or in combination with oral hypoglycemic agent, in the treatment of type 2 diabetic patients before, during, & after ramadan. J Indon Med Assoc 2011.
[42]
Hassanein M, Echtay AS, Malek R, et al. Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan. Diabetes Res Clin Pract 2018; 135: 218-26.
[http://dx.doi.org/10.1016/j.diabres.2017.11.027] [PMID: 29183844]
[43]
Nicolucci A, Ceriello A, Di Bartolo P, Corcos A, Orsini Federici M. Rapid-acting insulin analogues versus regular human insulin: A meta-analysis of effects on glycemic control in patients with diabetes. Diabetes Ther 2020; 11(3): 573-84.
[http://dx.doi.org/10.1007/s13300-019-00732-w] [PMID: 31873857]
[44]
Akram J, De Verga V, Group RS, Gravholt CH, Møller N, Schmitz O. Insulin lispro (Lys(B28), Pro(B29)) in the treatment of diabetes during the fasting month of Ramadan. Diabet Med 1999; 16(10): 867-74.
[http://dx.doi.org/10.1046/j.1464-5491.1999.00164.x] [PMID: 10547215]
[45]
Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368(9548): 1696-705.
[http://dx.doi.org/10.1016/S0140-6736(06)69705-5] [PMID: 17098089]
[46]
Godinho R, Mega C, Teixeira-de-Lemos E, et al. The place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: A “Me Too” or “the Special One” antidiabetic class? J Diabetes Res 2015; 2015: 1-28.
[http://dx.doi.org/10.1155/2015/806979] [PMID: 26075286]
[47]
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 2007; 298(2): 194-206.
[http://dx.doi.org/10.1001/jama.298.2.194] [PMID: 17622601]
[48]
Bajaj HS, Abouhassan T, Ahsan MR, Arnaout A, Hassanein M, Houlden RL. Diabetes Canada position statement for people with types 1 and 2 diabetes who fast during Ramadan. Can J Diabetes 2019; 43: 3-12.
[http://dx.doi.org/10.1016/j.jcjd.2018.04.007]
[49]
Brady EM, Davies MJ, Gray LJ, et al. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: The Treat 4 Ramadan Trial. Diabetes Obes Metab 2014; 16(6): 527-36.
[http://dx.doi.org/10.1111/dom.12249] [PMID: 24373063]
[50]
Khalifa AA, Alaaeldin MK. Safety and efficacy of liraglutide as an add-on therapy to pre-existing anti-diabetic regimens during ramadan, a prospective observational trial. J Diabetes Metab 2015; 06
[51]
Azar ST, Echtay A, Wan Bebakar WM, et al. Efficacy and safety of liraglutide compared to sulphonylurea during R amadan in patients with type 2 diabetes (LIRA-R amadan): A randomized trial. Diabetes Obes Metab 2016; 18(10): 1025-33.
[http://dx.doi.org/10.1111/dom.12733] [PMID: 27376711]
[52]
A comparative analysis of exenatide and gliclazide during the month of Ramadan. Diabet Med 2010; 27.
[53]
Hassanein MM, Sahay R, Hafidh K, et al. Safety of lixisenatide versus sulfonylurea added to basal insulin treatment in people with type 2 diabetes mellitus who elect to fast during Ramadan (LixiRam): An international, randomized, open-label trial. Diabetes Res Clin Pract 2019; 150: 331-41.
[http://dx.doi.org/10.1016/j.diabres.2019.01.035] [PMID: 30772385]
[54]
Hassanein M, Sahay RK, Malek R, et al. Real-world safety and effectiveness of iglarlixi in people with type 2 diabetes who fast during ramadan: Results from wave 1 of the SOLIRAM study. J Endocr Soc 2021; 5(S1): A334.
[http://dx.doi.org/10.1210/jendso/bvab048.681]
[55]
Deeb A, Babiker A, Sedaghat S, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Ramadan and other religious fasting by young people with diabetes. Pediatr Diabetes 2022; 23(8): 1512-28.
[http://dx.doi.org/10.1111/pedi.13447] [PMID: 36537522]
[56]
Deeb A. ISPAD clinical practice consensus guidelines: Fasting during ramadan by young people with diabetes. J Diabetes Res 2020; (1):
[57]
Baş VN, Uytun S, Torun YA. Diabetic euglycemic ketoacidosis in newly diagnosed type 1 diabetes mellitus during Ramadan fasting. J Pediatr Endocrinol Metab 2015; 28(3-4): 333-5.
[http://dx.doi.org/10.1515/jpem-2013-0497] [PMID: 25423670]
[58]
Friedrich I, Levy Y. Diabetic ketoacidosis during the Ramadan fast. Harefuah 2000; 138(1): 19-21, 86.
[PMID: 10868172]
[59]
Salti I, Bénard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: Results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004; 27(10): 2306-11.
[http://dx.doi.org/10.2337/diacare.27.10.2306] [PMID: 15451892]
[60]
Kaplan W, Afandi B. Blood glucose fluctuation during Ramadan fasting in adolescents with type 1 diabetes: Findings of continuous glucose monitoring. Diabetes Care 2015; 38(10): e162-3.
[http://dx.doi.org/10.2337/dc15-1108] [PMID: 26294662]
[61]
Afandi B, Kaplan W, al Hassani N, Hadi S, Mohamed A. Correlation between pre-ramadan glycemic control and subsequent glucose fluctuation during fasting in adolescents with type 1 diabetes. J Endocrinol Invest 2017; 40: 741-4.
[http://dx.doi.org/10.1007/s40618-017-0633-y]
[62]
Afandi B, Kaplan W, Majd L, Roubi S. Rate, Timing, and Severity of hypoglycemia in adolescents with type 1 diabetes during ramadan fasting: A study with freestyle libre flash glucose monitoring system. IJMBS 2018; 10(1): 9-11.
[http://dx.doi.org/10.4103/ijmbs.ijmbs_73_17]
[63]
Alfadhli EM. Higher rate of hyperglycemia than hypoglycemia during Ramadan fasting in patients with uncontrolled type 1 diabetes: Insight from continuous glucose monitoring system. Saudi Pharm J 2018; 26(7): 965-9.
[http://dx.doi.org/10.1016/j.jsps.2018.05.006] [PMID: 30416354]
[64]
Benbarka MM, Khalil AB, Beshyah SA, Marjei S, Awad SA. Insulin pump therapy in Moslem patients with type 1 diabetes during Ramadan fasting: an observational report. Diabetes Technol Ther 2010; 12(4): 287-90.
[http://dx.doi.org/10.1089/dia.2009.0130] [PMID: 20210567]
[65]
Khalil AB, Beshyah SA, Abu Awad SM, et al. Ramadan fasting in diabetes patients on insulin pump therapy augmented by continuous glucose monitoring: An observational real-life study. Diabetes Technol Ther 2012; 14(9): 813-8.
[http://dx.doi.org/10.1089/dia.2012.0061] [PMID: 22827507]
[66]
Elbarbary NS. Effectiveness of the low-glucose suspend feature of insulin pump during fasting during Ramadan in type 1 diabetes mellitus. Diabetes Metab Res Rev 2016; 32(6): 623-33.
[http://dx.doi.org/10.1002/dmrr.2781] [PMID: 26789012]
[67]
American Diabetes Association. 14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2021. Diabetes Care 2021; 44(44): S200-10.
[http://dx.doi.org/10.2337/dc21-S014] [PMID: 33298425]
[68]
Di Cianni G, Resi V, Lacaria E, Lencioni C. Hypoglycemia in diabetic pregnancy.Endocrinology. 2020; pp. 109-22.
[http://dx.doi.org/10.1159/000487095]
[69]
Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: A randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007; 30(4): 771-6.
[http://dx.doi.org/10.2337/dc06-1887] [PMID: 17392539]
[70]
Kimmerle R, Heinemann L, Delecki A, Berger M. Severe hypoglycemia incidence and predisposing factors in 85 pregnancies of type I diabetic women. Diabetes Care 1992; 15(8): 1034-7.
[http://dx.doi.org/10.2337/diacare.15.8.1034] [PMID: 1505305]
[71]
Evers IM, ter Braak EWMT, de Valk HW, van der Schoot B, Janssen N, Visser GHA. Risk indicators predictive for severe hypoglycemia during the first trimester of type 1 diabetic pregnancy. Diabetes Care 2002; 25(3): 554-9.
[http://dx.doi.org/10.2337/diacare.25.3.554] [PMID: 11874946]
[72]
Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, Johansen M, Damm P, Mathiesen ER. Hypoglycemia in pregnant women with type 1 diabetes: Predictors and role of metabolic control. Diabetes Care 2008; 31(1): 9-14.
[http://dx.doi.org/10.2337/dc07-1066] [PMID: 17909091]
[73]
Padmanabhan S, Lee VW, Mclean M, et al. The association of falling insulin requirements with maternal biomarkers and placental dysfunction: A prospective study of women with preexisting diabetes in pregnancy. Diabetes Care 2017; 40(10): 1323-30.
[http://dx.doi.org/10.2337/dc17-0391] [PMID: 28798085]
[74]
Dalfrà MG, Pacini G, Parretti E, Ragazzi E, Mello G, Lapolla A. Elevated insulin sensitivity and β-cell function during pregnancy in mothers of growth-restricted newborns. Am J Physiol Endocrinol Metab 2011; 301(1): E25-30.
[http://dx.doi.org/10.1152/ajpendo.00024.2011] [PMID: 21467301]
[75]
Langer O, Levy J, Brustman L, Anyaegbunam A, Merkatz R, Divon M. Glycemic control in gestational diabetes mellitus-How tight is tight enough: Small for gestational age versus large for gestational age? Am J Obstet Gynecol 1989; 161(3): 646-53.
[http://dx.doi.org/10.1016/0002-9378(89)90371-2] [PMID: 2782347]
[76]
Limesand SW, Rozance PJ, Zerbe GO, Hutton JC, Hay WW Jr. Attenuated insulin release and storage in fetal sheep pancreatic islets with intrauterine growth restriction. Endocrinology 2006; 147(3): 1488-97.
[http://dx.doi.org/10.1210/en.2005-0900] [PMID: 16339204]
[77]
Arturo Martínez-Piña D, Alexis Alvarado-Fernández G, González-Guevara E, Castillo-Pérez C, Romero-Luna G, Alejandro Torres-Ríos J. Hypoglycemia and brain: The effect of energy loss on neurons.Basics of Hypoglycemia. IntechOpen 2022.
[http://dx.doi.org/10.5772/intechopen.104210]
[78]
McNay E. Recurrent hypoglycemia increases anxiety and amygdala norepinephrine release during subsequent hypoglycemia. Front Endocrinol 2015; 20(6): 175.
[http://dx.doi.org/10.3389/fendo.2015.00175]
[79]
McCrimmon RJ. Consequences of recurrent hypoglycaemia on brain function in diabetes. Diabetologia 2021; 64(5): 971-7.
[http://dx.doi.org/10.1007/s00125-020-05369-0] [PMID: 33738528]
[80]
Kumar S, Diamond T. Ramadan fasting and maternal and fetal outcomes in pregnant women with diabetes mellitus: Literature review. Front Endocrinol 2022; 13: 900153.
[http://dx.doi.org/10.3389/fendo.2022.900153] [PMID: 35813638]
[81]
Nasa P, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: A missed diagnosis. World J Diabetes 2021; 12(5): 514-23.
[http://dx.doi.org/10.4239/wjd.v12.i5.514] [PMID: 33995841]
[82]
Frise CJ, Mackillop L, Joash K, Williamson C. Starvation ketoacidosis in pregnancy. Eur J Obstet Gynecol Reprod Biol 2013; 167(1): 1-7.
[http://dx.doi.org/10.1016/j.ejogrb.2012.10.005] [PMID: 23131345]
[83]
Sinha N, Venkatram S, Diaz-Fuentes G. Starvation ketoacidosis: a cause of severe anion gap metabolic acidosis in pregnancy. Case Rep Crit Care 2014; 2014: 1-4.
[http://dx.doi.org/10.1155/2014/906283] [PMID: 24963418]
[84]
Mirghani HM, Hamud OA. The effect of maternal diet restriction on pregnancy outcome. Am J Perinatol 2006; 23: 021-4.
[http://dx.doi.org/10.1055/s-2005-923435]
[85]
Murtaugh MA, Ferris AM, Capacchione CM, Reece A. Energy intake and glycemia in lactating women with type 1 diabetes. J Am Diet Assoc 1998; 98(6): 642-8.
[http://dx.doi.org/10.1016/S0002-8223(98)00147-3] [PMID: 9627620]
[86]
IDF Diabetes Atlas 9th edition. https://diabetesatlas.org/atlas/ninth-edition/
[87]
Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care 2012; 35(12): 2650-64.
[http://dx.doi.org/10.2337/dc12-1801] [PMID: 23100048]
[88]
LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: An endocrine society* clinical practice guideline. J Clin Endocrinol Metab 2019; 104(5): 1520-74.
[http://dx.doi.org/10.1210/jc.2019-00198] [PMID: 30903688]
[89]
Laatar R, Baccouch R, Borji R, Kachouri H, Rebai H, Sahli S. Ramadan fasting effects on postural control in the elderly: A comparison between fallers and non-fallers. J Relig Health 2019; 58(1): 28-40.
[http://dx.doi.org/10.1007/s10943-016-0323-7] [PMID: 27804006]
[90]
Laatar R, Borji R, Baccouch R, Zahaf F, Rebai H, Sahli S. Effects of Ramadan fasting on postural balance and attentional capacities in elderly people. J Nutr Health Aging 2016; 20(5): 553-60.
[http://dx.doi.org/10.1007/s12603-015-0620-y] [PMID: 27102795]
[91]
Greco D, Pisciotta M, Gambina F, Maggio F. Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol Diabetes 2010; 118(4): 215-9.
[http://dx.doi.org/10.1055/s-0029-1241823] [PMID: 20072965]
[92]
Ahmed SH, Chowdhury TA, Hussain S, et al. Ramadan and diabetes: A Narrative review and practice update. Diabetes Ther 2020; 11(11): 2477-520.
[http://dx.doi.org/10.1007/s13300-020-00886-y] [PMID: 32909192]
[93]
Hassanein M, Hussein Z, Shaltout I, et al. The DAR 2020 Global survey: Ramadan fasting during COVID-19 pandemic and the impact of older age on fasting among adults with type 2 diabetes. Diabetes Res Clin Pract 2021; 173: 108674.
[http://dx.doi.org/10.1016/j.diabres.2021.108674] [PMID: 33493579]
[94]
Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: A pooled analysis from a database of clinical trials. Diabetes Obes Metab 2011; 13(1): 55-64.
[http://dx.doi.org/10.1111/j.1463-1326.2010.01325.x] [PMID: 21114604]
[95]
Abstracts of the 74th Scientific Sessions of the American Diabetes Association, June 13-17, 2014, San Francisco, California. Diabetes 2014; 63(S3): A1-A822.
[96]
Qureshi NK. Acute complications associated with fasting in patients with diabetes during ramadan: Assessment and prevention. J Endocrinol Thyroid Res 2020; 5.
[http://dx.doi.org/10.19080/JETR.2020.05.555665]
[97]
Zhang H, Qin L, Sheng C-S, Niu Y, Gu H, Lu S. ASCVD risk stratification modifies the effect of HbA1c on cardiovascular events among patients with type 2 diabetes mellitus with basic to moderate risk. BMJ Open Diabetes Res Care 2020; 9(8): e000810.
[http://dx.doi.org/10.1136/bmjdrc-2019-000810]
[98]
Nelson AJ, O’Brien EC, Kaltenbach LA, Green JB, Lopes RD, Morse CG. Blood pressure–, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease. JAMA Netw Open 2022; 17(5): e2148030.
[http://dx.doi.org/10.1001/jamanetworkopen.2021.48030]
[99]
Nelson AJ, Peterson ED, Pagidipati NJ. Atherosclerotic cardiovascular disease and heart failure: Determinants of risk and outcomes in patients with diabetes. Prog Cardiovasc Dis 2019; 62(4): 306-14.
[http://dx.doi.org/10.1016/j.pcad.2019.07.001] [PMID: 31301314]
[100]
Wang CCL, Reusch JEB. Diabetes and cardiovascular disease: changing the focus from glycemic control to improving long-term survival. Am J Cardiol 2012; 110(9) (Suppl.): 58B-68B.
[http://dx.doi.org/10.1016/j.amjcard.2012.08.036] [PMID: 23062569]
[101]
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42(34): 3227-337.
[http://dx.doi.org/10.1093/eurheartj/ehab484] [PMID: 34458905]
[102]
Akhtar AM, Ghouri N, Chahal CAA, et al. Ramadan fasting: Recommendations for patients with cardiovascular disease. Heart 2022; 108(4): 258-65.
[http://dx.doi.org/10.1136/heartjnl-2021-319273] [PMID: 33990414]
[103]
Pozzilli P, David Leslie R, Chan J, et al. The A1c and ABCD of glycaemia management in type 2 diabetes: A physician’s personalized approach. Diabetes Metab Res Rev 2010; 26(4): 239-44.
[http://dx.doi.org/10.1002/dmrr.1092] [PMID: 20503255]
[104]
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55(6): 1577-96.
[http://dx.doi.org/10.1007/s00125-012-2534-0] [PMID: 22526604]
[105]
Mannucci E, Dicembrini I, Lauria A, Pozzilli P. Is glucose control important for prevention of cardiovascular disease in diabetes? Diabetes Care 2013; 36(S2): S259-63.
[http://dx.doi.org/10.2337/dcS13-2018] [PMID: 23882055]
[106]
Ramadan Rapid Review & Recommendations British Islamic Medical Association. BIMA 2020.
[107]
Sassi M, Chakroun T, Chouchène S, et al. Does lipid profile affect thrombin generation during ramadan fasting in patients with cardiovascular risks? Clin Appl Thromb Hemost 2017; 23(8): 980-6.
[http://dx.doi.org/10.1177/1076029616665920] [PMID: 27613563]
[108]
Al Suwaidi J, Bener A, Gehani AA, et al. Does the circadian pattern for acute cardiac events presentation vary with fasting? J Postgrad Med 2006; 52: 30.
[109]
Zhou M, Liu J, Hao Y, Liu J, Huo Y, Smith SC, et al. Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in china: Findings from the improving care for cardiovascular disease in china-acute coronary syndrome project. Cardiovasc Diabetol 2018; 17: 147.
[http://dx.doi.org/10.1186/s12933-018-0793-x]
[110]
Amin OA, Alaarag A. The safety of ramadan fasting following percutaneous coronary intervention. BMC Cardiovasc Disord 2020; 20(1): 489.
[http://dx.doi.org/10.1186/s12872-020-01784-8] [PMID: 33213367]
[111]
Chamsi-Pasha H, Ahmed WH. The effect of fasting in Ramadan on patients with heart disease. Saudi Med J 2004; 25(1): 47-51.
[PMID: 14758379]
[112]
Mousavi M, Mirkarimi SS, Rahmani G, Hosseinzadeh E, Salahi N. Ramadan fast in patients with coronary artery disease. Iran Red Crescent Med J 2014; 16(12): e7887.
[http://dx.doi.org/10.5812/ircmj.7887] [PMID: 25763250]
[113]
Al Suwaidi J, Bener A, Osman M, Al Merri A, Al Suwaidi J. The impact of diurnal fasting during Ramadan on the lipid profile, hs-CRP, and serum leptin in stable cardiac patients. Vasc Health Risk Manag 2011; 8: 7-14.
[http://dx.doi.org/10.2147/VHRM.S22894] [PMID: 22272070]
[114]
Bouida W, Beltaief K, Baccouche H, Sassi M, Dridi Z, Trabelsi I, et al. Effects of Ramadan fasting on aspirin resistance in type 2 diabetic patients. PLoS One 2018; 12(13): e0192590.
[http://dx.doi.org/10.1371/journal.pone.0192590]
[115]
Batarfi A, Alenezi H, Alshehri A, et al. Patient-guided modifications of oral anticoagulant drug intake during Ramadan fasting: a multicenter cross-sectional study. J Thromb Thrombolysis 2021; 51(2): 485-93.
[http://dx.doi.org/10.1007/s11239-020-02218-0] [PMID: 32666427]
[116]
Abazid RM, Khalaf HH, Sakr HI, et al. Effects of Ramadan fasting on the symptoms of chronic heart failure. Saudi Med J 2018; 39(4): 395-400.
[http://dx.doi.org/10.15537/smj.2018.4.22011] [PMID: 29619492]
[117]
M S, Ah SA, Sr S, Km B. Effect of ramadan fasting on body weight, (BP) and biochemical parameters in middle aged hypertensive subjects: An observational trial. J Clin Diagn Res 2014; 8(3): 16-8.
[PMID: 24783068]
[118]
Al-Jafar R, Zografou Themeli M, Zaman S, et al. Effect of religious fasting in ramadan on blood pressure: Results From LORANS (London Ramadan Study) and a meta-analysis. J Am Heart Assoc 2021; 10(20): e021560.
[http://dx.doi.org/10.1161/JAHA.120.021560] [PMID: 34619991]
[119]
Habbal R, Azzouzi L, Adnan K, Tahiri A, Chraibi N. Variations of blood pressure during the month of Ramadan. Arch Mal Coeur Vaiss 1998; 91(8): 995-8.
[PMID: 9749152]
[120]
Eldeeb A, Mahmoud M, Ibrahim A, Yousef E, Sabry A. Effect of Ramadan fasting on arterial stiffness parameters among Egyptian hypertensive patients with and without chronic kidney disease. Saudi J Kidney Dis Transpl 2020; 31(3): 582-8.
[http://dx.doi.org/10.4103/1319-2442.289444] [PMID: 32655044]
[121]
Bouida W, Baccouche H, Sassi M, Dridi Z, Chakroun T, Hellara I. Effects of Ramadan fasting on platelet reactivity in diabetic patients treated with clopidogrel. Thromb J 2017; 15: 15.
[http://dx.doi.org/10.1186/s12959-017-0138-0]
[122]
Aslam M, Healy MA. Compliance and drug therapy in fasting Moslem patients. J Clin Pharm Ther 1986; 11(5): 321-5.
[http://dx.doi.org/10.1111/j.1365-2710.1986.tb00859.x] [PMID: 3782478]
[123]
Salam AM, AlBinali HA, Salim I, et al. Impact of religious fasting on the burden of atrial fibrillation: A population-based study. Int J Cardiol 2013; 168(3): 3042-3.
[http://dx.doi.org/10.1016/j.ijcard.2013.04.131] [PMID: 23642825]
[124]
Hyltén-Cavallius L, Iepsen EW, Wewer Albrechtsen NJ, et al. Patients with long-QT syndrome caused by impaired hERG -Encoded K v 11.1 potassium channel have exaggerated endocrine pancreatic and incretin function associated with reactive hypoglycemia. Circulation 2017; 135(18): 1705-19.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024279] [PMID: 28235848]
[125]
Marques JLB, George E, Peacey SR, et al. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med 1997; 14(8): 648-54.
[http://dx.doi.org/10.1002/(SICI)1096-9136(199708)14:8<648:AID-DIA418>3.0.CO;2-1] [PMID: 9272590]
[126]
Rothenbuhler A, Petit Bibal C, Le Fur S, Bougneres P. Effects of a controlled hypoglycaemia test on QTc in adolescents with Type 1 diabetes. Diabet Med 2008; 25(12): 1483-5.
[http://dx.doi.org/10.1111/j.1464-5491.2008.02599.x] [PMID: 19046250]
[127]
Salam AM, Sulaiman K, Alsheikh-Ali AA, et al. Acute heart failure presentations and outcomes during the fasting month of Ramadan: an observational report from seven Middle Eastern countries. Curr Med Res Opin 2018; 34(2): 237-45.
[http://dx.doi.org/10.1080/03007995.2017.1376629] [PMID: 28871820]
[128]
Çomoğlu S, Temiı̇zhan A, Peşiı̇nciı̇ E, Tandoğan I, Özbakir ş. Effects of ramadan fasting on stroke. Turk J Med Sci 2003; 33: 237-41.
[129]
Yazdeen AF, Hummadi MF, Al-Tawil NG, AlShimmery IK. Association between Ramadan Fasting Association between Ramadan Fasting and cerebrovascular diseases. Zanco J Med Sci 2017; p. 21.
[130]
Assy MH, Awd M, Elshabrawy AM, Gharieb M. Effect of Ramadan fasting on incidence of cerebrovascular stroke in Egyptian patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2019; 151: 299-304.
[http://dx.doi.org/10.1016/j.diabres.2019.03.012] [PMID: 30902673]
[131]
Bener A, Hamad A, Fares A, Al-Sayed HM, Al-Suwaidi J. Is there any effect of Ramadan fasting on stroke incidence? Singapore Med J 2006; 47(5): 404-8.
[PMID: 16645691]
[132]
Zhuo Y, Wu J, Qu Y, et al. Clinical risk factors associated with recurrence of ischemic stroke within two years. Medicine 2020; 99(26): e20830.
[http://dx.doi.org/10.1097/MD.0000000000020830] [PMID: 32590771]
[133]
Lioutas VA, Ivan CS, Himali JJ, et al. Incidence of transient ischemic attack and association with long-term risk of stroke. JAMA 2021; 325(4): 373-81.
[http://dx.doi.org/10.1001/jama.2020.25071] [PMID: 33496774]
[134]
Amarenco P, Lavallée PC, Labreuche J, et al. One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med 2016; 374(16): 1533-42.
[http://dx.doi.org/10.1056/NEJMoa1412981] [PMID: 27096581]
[135]
Amarenco P, Lavallée PC, Monteiro Tavares L, et al. Five-year risk of stroke after TIA or minor ischemic stroke. N Engl J Med 2018; 378(23): 2182-90.
[http://dx.doi.org/10.1056/NEJMoa1802712] [PMID: 29766771]
[136]
Kamil S, Sehested TSG, Carlson N, Houlind K, Lassen JFN, Bang C, et al. Diabetes and risk of peripheral artery disease in patients undergoing first-time coronary angiography between 2000 and 2012 – a nationwide study. BMC Cardiovasc Disord 2012; 24(19): 234.
[http://dx.doi.org/10.1186/s12872-019-1213-1]
[137]
Fowkes FGR, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet 2013; 382(9901): 1329-40.
[http://dx.doi.org/10.1016/S0140-6736(13)61249-0] [PMID: 23915883]
[138]
Arora E, Maiya AG, Devasia T, Bhat R, Kamath G. Prevalence of peripheral arterial disease among type 2 diabetes mellitus in coastal Karnataka. Diabetes Metab Syndr 2019; 13(2): 1251-3.
[http://dx.doi.org/10.1016/j.dsx.2019.02.003] [PMID: 31336473]
[139]
Soyoye DO, Ikem RT, Kolawole BA, Oluwadiya KS, Bolarinwa RA, Adebayo OJ. Prevalence and correlates of peripheral arterial disease in nigerians with type 2 diabetes. Adv Med 2016; 2016: 1-6.
[http://dx.doi.org/10.1155/2016/3529419] [PMID: 27800544]
[140]
Soyoye DO, Abiodun OO, Ikem RT, Kolawole BA, Akintomide AO. Diabetes and peripheral artery disease: A review. World J Diabetes 2021; 12(6): 827-38.
[http://dx.doi.org/10.4239/wjd.v12.i6.827] [PMID: 34168731]
[141]
Al-Arouj M, Assaad-Khalil S, Buse J, et al. Recommendations for management of diabetes during Ramadan: Update 2010. Diabetes Care 2010; 33(8): 1895-902.
[http://dx.doi.org/10.2337/dc10-0896] [PMID: 20668157]
[142]
Hassan A, Meo SA, Usmani AM, Shaikh TJ. Diabetes during Ramadan - PRE-approach model: Presentation, risk stratification, education. Eur Rev Med Pharmacol Sci 2014; 18(12): 1798-805.
[PMID: 24992624]
[143]
Uccioli L, Meloni M, Izzo V, Giurato L, Merolla S, Gandini R. Critical limb ischemia: Current challenges and future prospects. Vasc Health Risk Manag 2018; 14: 63-74.
[http://dx.doi.org/10.2147/VHRM.S125065] [PMID: 29731636]
[144]
Petrauskiene V, Falk M, Waernbaum I, Norberg M, Eriksson JW. The risk of venous thromboembolism is markedly elevated in patients with diabetes. Diabetologia 2005; 48(5): 1017-21.
[http://dx.doi.org/10.1007/s00125-005-1715-5] [PMID: 15778859]
[145]
Saadatnia M, Zare M, Fatehi F, Ahmadi A. The effect of fasting on cerebral venous and dural sinus thrombosis. Neurol Res 2009; 31(8): 794-8.
[http://dx.doi.org/10.1179/016164109X12445505689481] [PMID: 19723447]
[146]
Borhani Haghighi A, Ashjazadeh N, Safari A, Cruz-Flores S. Cerebral venous sinus thrombosis in Iran: Cumulative data, shortcomings and future directions. Iran Red Crescent Med J 2012; 14(12): 805-10.
[http://dx.doi.org/10.5812/ircmj.3728] [PMID: 23483618]
[147]
Al Wakeel JS. Kidney function and metabolic profile of chronic kidney disease and hemodialysis patients during Ramadan fasting. Iran J Kidney Dis 2014; 8(4): 321-8.
[PMID: 25001139]
[148]
NasrAllah MM, Osman NA. Fasting during the month of Ramadan among patients with chronic kidney disease: Renal and cardiovascular outcomes. Clin Kidney J 2014; 7(4): 348-53.
[http://dx.doi.org/10.1093/ckj/sfu046] [PMID: 25349694]
[149]
Disease K. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2022; 102(5S): S1-S127.
[PMID: 36272764]
[150]
Fangel MV, Nielsen PB, Kristensen JK, et al. Albuminuria and risk of cardiovascular events and mortality in a general population of patients with type 2 diabetes without cardiovascular disease: A danish cohort study. Am J Med 2020; 133(6): e269-79.
[http://dx.doi.org/10.1016/j.amjmed.2019.10.042] [PMID: 32205071]
[151]
Bragazzi N. Ramadan fasting and chronic kidney disease: Does estimated glomerular filtration rate change after and before Ramadan? Insights from a mini meta-analysis. Int J Nephrol Renovasc Dis 2015; 8: 53-7.
[http://dx.doi.org/10.2147/IJNRD.S61718] [PMID: 26082658]
[152]
Malik S, Bhanji A, Abuleiss H, et al. Effects of fasting on patients with chronic kidney disease during Ramadan and practical guidance for healthcare professionals. Clin Kidney J 2021; 14(6): 1524-34.
[http://dx.doi.org/10.1093/ckj/sfab032] [PMID: 34079617]
[153]
Sheashaa HA, Matter YELS, Refaie AF. Effect of Ramadan fasting on patients with different kidney diseases: An updated review. J Egypt Soc Nephrol Transplant 2018; 18(1): 1.
[http://dx.doi.org/10.4103/jesnt.jesnt_13_17]
[154]
Yucecan NKS, Yücecan S. Some behavioural changes observed among fasting subjects, their nutritional habits and energy expenditure in Ramadan. Int J Food Sci Nutr 2000; 51(2): 125-34.
[http://dx.doi.org/10.1080/096374800100822] [PMID: 10953756]
[155]
Qurashi S, Tamimi A, Jaradat M, Al Sayyari A. Effect of fasting for Ramadan on kidney graft function during the hottest month of the year (August) in Riyadh, Saudi Arabia. Exp Clin Transplant 2012; 10(6): 551-3.
[http://dx.doi.org/10.6002/ect.2012.0139] [PMID: 22920156]
[156]
Hejaili F, Qurashi S, Binsalih S, Jaradt M, Al Sayyari A. Effect of repeated ramadan fasting in the hottest months of the year on renal graft function. Nephrourol Mon 2014; 6(2): e14362.
[http://dx.doi.org/10.5812/numonthly.14362] [PMID: 24719821]
[157]
Said T, Nampoory MRN, Haleem MA, et al. Ramadan fast in kidney transplant recipients: A prospective comparative study. Transplant Proc 2003; 35(7): 2614-6.
[http://dx.doi.org/10.1016/j.transproceed.2003.08.072] [PMID: 14612040]
[158]
Kamar MEG, Orabi AA, Salem IM, El-Shabrawy AM. Effect of ramadan fasting on diabetic micro-vascular complications 2014; 20: 193.
[159]
Sun B, Luo Z, Zhou J. Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications. Cardiovasc Diabetol 2021; 20(9)
[http://dx.doi.org/10.1186/s12933-020-01200-7]
[160]
Aldawi N, Darwiche G, Abusnana S, Elbagir M, Elgzyri T. Initial increase in glucose variability during Ramadan fasting in non-insulin-treated patients with diabetes type 2 using continuous glucose monitoring. Libyan J Med 2019; 14(1): 1535747.
[http://dx.doi.org/10.1080/19932820.2018.1535747] [PMID: 30348064]
[161]
Zhang ZY, Miao LF, Qian LL, et al. Molecular mechanisms of glucose fluctuations on diabetic complications. Front Endocrinol 2019; 10: 640.
[http://dx.doi.org/10.3389/fendo.2019.00640] [PMID: 31620092]
[162]
Targher G, Bertolini L, Zenari L, et al. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. Diabet Med 2008; 25(1): 45-50.
[http://dx.doi.org/10.1111/j.1464-5491.2007.02327.x] [PMID: 18199131]
[163]
Hu YM, Zhao LH, Zhang XL, Cai HL, Huang HY, Xu F. Association of glycaemic variability evaluated by continuous glucose monitoring with diabetic peripheral neuropathy in type 2 diabetic patients. Endocrine 2018; 60: 292-300.
[164]
Zhang X, Yang X, Sun B, Zhu C. Perspectives of glycemic variability in diabetic neuropathy: A comprehensive review. Commun Biol 2021; 4: 1366.
[http://dx.doi.org/10.1038/s42003-021-02896-3]
[165]
Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010; 12(4): 288-98.
[http://dx.doi.org/10.1111/j.1463-1326.2009.01160.x] [PMID: 20380649]
[166]
Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26(5): 1553-79.
[http://dx.doi.org/10.2337/diacare.26.5.1553] [PMID: 12716821]
[167]
Omran D, Al Soda M, Bahbah E, Esmat G, Shousha H, Elgebaly A, et al. Predictors of severity and development of critical illness of Egyptian COVID-19 patients: A multicenter study. PLoS One 2021; 16: e0256203.
[http://dx.doi.org/10.1371/journal.pone.0256203]
[168]
AbdelGhaffar MM, Omran D, Elgebaly A, Bahbah EI, Afify S, AlSoda M, et al. Prediction of mortality in hospitalized Egyptian patients with Coronavirus disease-2019: A multicenter retrospective study. PLoS One 2022; 17: e0262348.
[http://dx.doi.org/10.1371/journal.pone.0262348]
[169]
Turk Wensveen T, Gašparini D, Rahelić D, Wensveen FM. Type 2 diabetes and viral infection; cause and effect of disease. Diabetes Res Clin Pract 2021; 172: 108637.
[http://dx.doi.org/10.1016/j.diabres.2020.108637] [PMID: 33352263]
[170]
Önmez A, Gamsızkan Z, Özdemir Ş, et al. The effect of COVID-19 lockdown on glycemic control in patients with type 2 diabetes mellitus in Turkey. Diabetes Metab Syndr 2020; 14(6): 1963-6.
[http://dx.doi.org/10.1016/j.dsx.2020.10.007] [PMID: 33059299]
[171]
D’Onofrio L, Pieralice S, Maddaloni E, et al. Effects of the COVID-19 lockdown on glycaemic control in subjects with type 2 diabetes: The glycalock study. Diabetes Obes Metab 2021; 23(7): 1624-30.
[http://dx.doi.org/10.1111/dom.14380] [PMID: 33764666]
[172]
Karatas S, Yesim T, Beysel S. Impact of lockdown COVID-19 on metabolic control in type 2 diabetes mellitus and healthy people. Prim Care Diabetes 2021; 15(3): 424-7.
[http://dx.doi.org/10.1016/j.pcd.2021.01.003] [PMID: 33441263]
[173]
Biamonte E, Pegoraro F, Carrone F, et al. Weight change and glycemic control in type 2 diabetes patients during COVID-19 pandemic: the lockdown effect. Endocrine 2021; 72(3): 604-10.
[http://dx.doi.org/10.1007/s12020-021-02739-5] [PMID: 33950348]
[174]
Khan H, Chowdhury A, Lasker SS, Chowdhury TA. The effect of COVID-19 on Ramadan fasting in people with diabetes in East London 2020: The East London diabetes in Ramadan survey. Diabetes Res Clin Pract 2020; 169: 108476.
[http://dx.doi.org/10.1016/j.diabres.2020.108476] [PMID: 33002549]
[175]
Zaina A, Tarabeih W, Abid A, Kassem S. COVID-19 pandemic and ramadan fasting among patients with type 2 diabetes mellitus. Isr Med Assoc J 2021; 23(4): 203-7.
[PMID: 33899349]
[176]
Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Psychosocial care for people with diabetes: A position statement of the american diabetes association. Diabetes Care 2016; 39(12): 2126-40.
[http://dx.doi.org/10.2337/dc16-2053] [PMID: 27879358]
[177]
Azizi F. Research in Islamic fasting and health. Ann Saudi Med 2002; 22(3-4): 186-91.
[http://dx.doi.org/10.5144/0256-4947.2002.186] [PMID: 17159392]
[178]
Meo SA, Hassan A. Physiological changes during fasting in Ramadan. J Pak Med Assoc 2015; 65(5): S6-S14.
[PMID: 26013791]
[179]
Turner R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854-65.
[http://dx.doi.org/10.1016/S0140-6736(98)07037-8] [PMID: 9742977]
[180]
Lessan N, Hannoun Z, Hasan H, Barakat MT. Glucose excursions and glycaemic control during Ramadan fasting in diabetic patients: Insights from continuous glucose monitoring (CGM). Diabetes Metab 2015; 41(1): 28-36.
[http://dx.doi.org/10.1016/j.diabet.2014.11.004] [PMID: 25497966]
[181]
Al-Ozairi E, El Samad A, Al Kandari J, Aldibbiat AM. Intermittent fasting could be safely achieved in people with type 1 diabetes undergoing structured education and advanced glucose monitoring. Front Endocrinol 2019; 10: 849.
[182]
Alsaeed D, Al-Kandari J, Al-Ozairi E. Experiences of people with type 1 diabetes fasting Ramadan following structured education: A qualitative study. Diabetes Res Clin Pract 2019; 153: 157-65.
[http://dx.doi.org/10.1016/j.diabres.2019.05.021] [PMID: 31150719]
[183]
Shaltout I, Zakaria A, Abdelwahab AM, Hamed A, Elsaid NH, Attia MA. Culturally based pre-Ramadan education increased benefits and reduced hazards of Ramadan fasting for type 2 diabetic patients. J Diabetes Metab Disord 2020; 19(1): 179-86.
[http://dx.doi.org/10.1007/s40200-020-00489-1] [PMID: 32550167]
[184]
Sun J, Han K, Xu M, et al. Blood viscosity in subjects with type 2 diabetes mellitus: Roles of hyperglycemia and elevated plasma fibrinogen. Front Physiol 2022; 13: 827428.
[http://dx.doi.org/10.3389/fphys.2022.827428] [PMID: 35283762]

Rights & Permissions Print Cite
Article Metrics
29
1
© 2024 Bentham Science Publishers | Privacy Policy